Received by email:

File: Vodis - Debt Settlement NR (10.14.16).pdf

05:00 PT - News Release 
VP Close 2016-10-14 C$ 0.14

Mr. Ivan Miliovski reports

                             VODIS ANNOUNCES DEBT SETTLEMENT

October 14, 2016   Vancouver, British Columbia   Vodis Pharmaceuticals Inc. (CSE: VP / FSE:
1JV) ("Vodis" or the "Company") announces that the Company has agreed to settle a total of
$858,650 in outstanding debt owed to various creditors & lenders for expenses and costs
incurred in order to sustain the Company's operations and development.

The debt will be settled by the issuance of a total of 13,210,000 units of the Company (the
"Debt Shares") at a deemed value of $0.065 per unit. Each unit will be comprised of one (1)
common share and one (1) share purchase warrant. Each warrant will be exercisable at a price
of $0.08 for two (2) years from the date of issuance.

Additionally in consideration for a loan provided by a non insider of the Company and under the
terms of the loan agreement, Vodis will issue an additional 600,000 common shares of the
Company (the "Bonus Shares") at a deemed price of $0.065 per share. All Shares will be subject
to a hold period of four months and a day from the date of closing.

About Vodis Pharmaceuticals Inc.

Vodis is one of North America's foremost brand names in the medical and recreational
marijuana business with operations in both the United States and Canada. Its master grow
teams have consistently won or placed at each competition they have entered with t heir "VIP"
brand. The Company, with facilities in BC and Washington State, is also actively looking into
expansion opportunities in other countries and states in the United States.

While Vodis Pharmaceuticals and its subsidiaries cannot have any interest whatsoever in any
proceeds as a result of production, processing or retail activities in the United States, it can
license its brand, production and consulting services to approved Washington State license
holders to ensure that all products produced under the Vodis Pharmaceuticals program and/or
associated under the VIP brand meet or exceed the Vodis brand quality standards.

For further information, please contact:
Ivan Miliovski
Chief Executive Officer
Vodis Innovative Pharmaceuticals Inc.
8788 River Rd, Delta, V4G 1B4, Canada
Cell: 778-242-9677
Website: www.vodis.ca
 The Canadian Securities Exchange has neither approved nor disapproved the contents of this
news release and accepts no responsibility for the adequacy or accuracy hereof.

Forward-Looking Information:

Certain information contained herein may constitute "forward-looking information" under Canadian
securities legislation. Generally, forward-looking information can be identified by the use of forward-
looking terminology such as "expects" or "it is expected", or variations of such words and phrases or
statements that certain actions, events or results "will" occur. Forward-looking statements are based on
the opinions and estimates of management as of the date such statements are made and they are
subject to known and unknown risks, uncertainties and other factors that may cause the actual results,
level of activity, performance or achievements of the Company to be materially different from those
expressed or implied by such forward-looking statements or forward-looking information, including: the
use of proceeds of this financing. Although management of the Company has attempted to identify
important factors that could cause actual results to differ materially from those contained in forward-
looking statements or forward-looking information, there may be other factors that cause results not to
be as anticipated, estimated or intended. There can be no assurance that such statements will prove to
be accurate, as actual results and future events could differ materially from those anticipated in such
statements. Accordingly, readers should not place undue reliance on forward-looking statements and
forward-looking information. The Company does not undertake to update any forward-looking
statements or forward-looking information that is incorporated by reference herein, except as required
by applicable securities laws.